Cancelled by the investigator Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

Clinical Study of NK Cells in the Treatment of Novel Coronavirus Pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000030509

Enrollment

Unknown

Registered

2020-03-05

Start date

2020-03-13

Completion date

Unknown

Last updated

2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

experimental group:Intravenous infusion of NK cells on day 0,3 and 6 , 1*107—1*108/kg body weight of NK cells each day.

control group:Sodium Potassium Magnesium Calcium and Glucose Injection.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male or female aged 18-80 years old; 2. Patients with confirmed novel coronavirus-infected pneumonia; 3. Diagnosed as moderate cases of COVID-19 with fever and respiratory symptoms and image showing pneumonia; 4. Voluntarily sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Sever cases with shock, acute respiratory distress syndrome; 2. Multiple organ failure; 3. Pregnant or lactating women; 4. Cases with malignant disease, autoimmune disease or sever diseases of immune immune system, such as: HIV infection; 5. Major organ transplantation; 6. Other conditions that are not suitable for enrollment.

Design outcomes

Primary

Measure	Time frame
Time and rate of novel coronavirus become negative.;	—

Secondary

Measure	Time frame
Level of IL2, IL4, IL6, IL10, TNF-alpha and IFN-gama;Routine blood test;lymphocyte subsets;	—

Countries

China

Contacts

Public ContactKaijiang Yu

The First Hospital of Harbin Medical University

drkaijiang@163.com+86 0451-53602290

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026